



Response document for MHRA public consultation on the  
proposal to make Arthriex 750mg and 1500mg Film-coated Tablets available in Pharmacies  
Ref: ARM96

ANNEX 1

**Your details**

**Name:** Yogeeta Bhupal

**Position (if applicable):** Professional Support Pharmacist

**Organisation (if applicable):** Royal Pharmaceutical Society

**Email:** consultations@rpharms.com

**a. Do you consider that Arthriex 750mg and 1500mg Film-coated Tablets should be available as a Pharmacy medicine?**

Yes                       No                       Not sure

Please provide any comments or evidence to support your response:

The Royal Pharmaceutical Society supports the proposal to make Arthriex 750mg and 1500mg film coated tablets available as a Pharmacy medicine. Pharmacists are experts in medicines and are well trained to ensure safe supply of medicines to the public. Pharmacists are currently able to sell products for the treatment of osteoarthritis and products containing glucosamine with appropriate advice on management and associated care.

**b. Do you have any specific comments on the leaflet or the label provided in the public reclassification report? In particular:**

- **If you are a potential patient, do you find the patient information leaflet (Annex 2) and the label (Annex 3) understandable?**
- **If you are a pharmacist or healthcare professional would you be confident to supply this product if suitable pharmacy training was provided?**

The patient information leaflet (PIL) makes reference to informing the doctor if the patient does not feel better or if they feel worse after 2-3 months, we would suggest the addition of pharmacist as pharmacists are also able to provide additional advice on medication and management of conditions.

Section on if you take more Arthriex states "*if a patient takes large quantities they must consult their doctor or hospital*" we would suggest the addition of pharmacist as pharmacists are also trained to advise on overdose and may be more accessible than a doctor.

We feel with appropriate training healthcare professionals would be confident to make a safe and effective supply to patients, with additional material such as Summary of Product Characteristics to supplement training.

**c. Do you have any other comments on the reclassification?**

Is there a limit on the quantity that can be supplied at any one time as a pharmacy medicine?

**d. The MHRA may publish consultation responses. Do you want your response to remain confidential?**

Yes                       Partially\*                       No

\*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email ([reclassification@mhra.gsi.gov.uk](mailto:reclassification@mhra.gsi.gov.uk)) to arrive by **xxxxxx 2017**. Contributions received after that date cannot be included in the exercise.